A multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of apraglutide in adult subjects with short bowel syndrome and intestinal failure (SBS-IF)
Latest Information Update: 22 May 2024
At a glance
- Drugs Apraglutide (Primary)
- Indications Intestinal disorders; Short bowel syndrome
- Focus Registrational; Therapeutic Use
- Acronyms STARS
- Sponsors Ironwood Pharmaceuticals; VectivBio
- 21 May 2024 Results presented in an Ironwood Pharmaceuticals media release.
- 21 May 2024 According to an Ironwood Pharmaceuticals media release, company will present late-breaking data during the 2024 Digestive Disease Week (DDW) meeting from this pivotal Phase III clinical trial, STARS, assessing the efficacy and safety of once-weekly subcutaneous apraglutide in adult patients with short bowel syndrome with intestinal failure (SBS-IF).
- 02 May 2024 Status changed from active, no longer recruiting to completed.